Results 171 to 180 of about 28,272 (264)

PCSK9 as a Biomarker for Cardiovascular Risk [PDF]

Background: Proprotein convertase subtilisin/kexin 9 (PCSK9) is a protein that prevents low-density lipoprotein (LDL) clearance from plasma through degradation of low-density lipoprotein receptors (LDL-R).
McKinnon, Tyler J
core   +1 more source

Table_1_Association Between Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations and Cardiovascular Events in Cardiovascular Disease: A Systemic Review and Meta-Analysis.DOCX

, 2021
Jiahui Liu (724342), Fangfang Fan (312738), Xingyu Luo (3684229), Wenjun Ji (822811), Yaokun Liu (11743949), Yan Zhang (8098), Bo Zheng (170888)   +6 more
openalex   +2 more sources

Proprotein convertase subtilisin/kexin type 9 (PCSK9) [PDF]

Science-Business eXchange, 2012
openaire   +1 more source

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in aortic stenosis - Is this the light at the end of the tunnel for patients with aortic stenosis?

, 2021
Sourabh Agstam, Tushar Agarwal, Anunay Gupta, Sandeep Bansal   +3 more
openalex   +1 more source

Proprotein convertase subtilisin kexin type 9 (PCSK9) [PDF]

Science-Business eXchange, 2009
openaire   +1 more source

Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (<i>PCSK9</i>) Gain-of-Function Mutations

, 2015
Hayato Tada, Masa‐aki Kawashiri, Taiji Yoshida, Ryota Teramoto, Atsushi Nohara, Tetsuo Konno, Akihiro Inazu, Hiroshi Mabuchi, Masakazu Yamagishi, Kenshi Hayashi   +9 more
openalex   +2 more sources

Proprotein Convertase Subtilisin/Kexin Type 9 Measurement [PDF]

, 2020
openaire   +1 more source

Polymorphisms in the proprotein convertase subtilisin/kexin type 9 gene in clinically diagnosed patients with familial hypercholesterolemia. [PDF]

Rev Assoc Med Bras (1992)
Costa ALDS, Santos JED, Salgado Junior W, Bertoncini-Silva C, Bizari L, Moura GSPL, Liberatore Junior RDR, Zorzo RA, Suen VMM.   +8 more
europepmc   +1 more source

Proprotein convertase subtilisin/ kexin type 9 levels and arterial function

Atherosclerosis, 2018
Koutagiar, I., Vlachopoulos, C., Terentes-Printzios, D., Skoumas, J., Skliros, N., Rigatou, A., Ioakeimidis, N., Pantou, S., Georgakopoulos, C., Miliou, A., Tousoulis, D.   +10 more
openaire   +2 more sources

A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis. [PDF]

Sci Rep
Dermiki-Gkana F, Gravel CA, Kontogiorgis C, Douros A.   +3 more
europepmc   +1 more source